Tomohiro Hayashi1, Tomoya Yamashita1, Hikaru Watanabe2, Kenjiro Kami3, Naofumi Yoshida1, Tokiko Tabata1, Takuo Emoto1, Naoto Sasaki4, Taiji Mizoguchi1, Yasuhiro Irino5, Ryuji Toh5, Masakazu Shinohara6, Yuko Okada7, Wataru Ogawa7, Takuji Yamada2, Ken-Ichi Hirata1. 1. Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine. 2. School of Life Science and Technology, Tokyo Institute of Technology. 3. Human Metabolome Technologies. 4. Department of Medical Pharmaceutics, Kobe Pharmaceutical University. 5. Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine. 6. Division of Epidemiology and The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine. 7. Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine.
Abstract
BACKGROUND: Gut microbiome composition or circulating microbiome-related metabolites in patients with heart failure (HF) have not been investigated at different time points (i.e., in the decompensated (Decomp) and compensated (Comp) phases). Methods and Results: We prospectively enrolled 22 patients admitted for HF and 11 age-, sex-, and comorbidity-matched hospitalized control subjects without a history of HF. Gut flora and plasma microbiome-related metabolites were evaluated by amplicon sequencing of the bacterial 16S ribosomal RNA gene and capillary electrophoresis time-of-flight mass spectrometry, respectively. HF patients were evaluated in both the Decomp and Comp phases during hospitalization. The phylum Actinobacteria was enriched in HF patients compared with control subjects. At the genus level, Bifiodobacterium was abundant while Megamonas was depleted in HF patients. Meanwhile, plasma concentration of trimethylamine N-oxide (TMAO), a gut microbiome-derived metabolite, was increased in HF patients (Decomp HF vs. control, P=0.003; Comp HF vs. control, P=0.004). A correlation analysis revealed positive correlations between the abundance of the genus Escherichia/Shigella and levels of TMAO and indoxyl sulfate (IS, a microbe-dependent uremic toxin) in Comp HF (TMAO: r=0.62, P=0.002; IS: r=0.63, P=0.002). Escherichia/Shigella was more abundant in Decomp than in Comp HF (P=0.030). CONCLUSIONS: Our results suggest that gut microbiome composition and microbiome-related metabolites are altered in HF patients.
BACKGROUND:Gut microbiome composition or circulating microbiome-related metabolites in patients with heart failure (HF) have not been investigated at different time points (i.e., in the decompensated (Decomp) and compensated (Comp) phases). Methods and Results: We prospectively enrolled 22 patients admitted for HF and 11 age-, sex-, and comorbidity-matched hospitalized control subjects without a history of HF. Gut flora and plasma microbiome-related metabolites were evaluated by amplicon sequencing of the bacterial 16S ribosomal RNA gene and capillary electrophoresis time-of-flight mass spectrometry, respectively. HF patients were evaluated in both the Decomp and Comp phases during hospitalization. The phylum Actinobacteria was enriched in HF patients compared with control subjects. At the genus level, Bifiodobacterium was abundant while Megamonas was depleted in HF patients. Meanwhile, plasma concentration of trimethylamine N-oxide (TMAO), a gut microbiome-derived metabolite, was increased in HF patients (Decomp HF vs. control, P=0.003; Comp HF vs. control, P=0.004). A correlation analysis revealed positive correlations between the abundance of the genus Escherichia/Shigella and levels of TMAO and indoxyl sulfate (IS, a microbe-dependent uremic toxin) in Comp HF (TMAO: r=0.62, P=0.002; IS: r=0.63, P=0.002). Escherichia/Shigella was more abundant in Decomp than in Comp HF (P=0.030). CONCLUSIONS: Our results suggest that gut microbiome composition and microbiome-related metabolites are altered in HF patients.
Entities:
Keywords:
Gut microbiome; Heart failure; Metabolites
Authors: Ana F Diallo; Mark B Lockwood; Katherine A Maki; Alexis T Franks; Abhrarup Roy; Rosario Jaime-Lara; Paule V Joseph; Wendy A Henderson; Seon Yoon Chung; Jacqueline McGrath; Stefan J Green; Anne M Fink Journal: Biol Res Nurs Date: 2020-07-29 Impact factor: 2.522